Drug intelligence / Profile preview

TK-kRAS

Development stage: Preclinical
Lead developer: Tosk

Overview

TK-kRAS is an experimental oncology drug from Tosk that is being developed to inhibit the activity of proteins produced by mutant KRAS genes, a key oncogenic driver in up to roughly 30% of all cancers and high proportions of pancreatic, colorectal, and lung tumors.[1][3] Using Tosk’s proprietary Genetically Modified Fly technology, TK-kRAS was identified as a KRAS gene modulator intended to block signaling from mutant KRAS variants that promote tumor growth, with the aim of providing a targeted therapy option for a broad spectrum of KRAS‑mutant solid tumors.[1][3][9]

Targets

Kirsten rat sarcoma viral oncogene homolog mutated protein

Beyond the preview

Go deeper on TK-kRAS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TK-kRAS.